[{"arm_notes": "", "treatment_id": null, "treatment_name": "TODO PreventionIntervention group2: Participants in this group will receive two doses (IM) of Sinopharm vaccine 21 days apart followed by a nasal spray 51 days after the first dose (day 0). Nasal spray contains an adjuvant made in Razi Institute.", "treatment_type": "TODO", "pharmacological_treatment": "TODO"}, {"arm_notes": "", "treatment_id": null, "treatment_name": "TODO PreventionIntervention group1: Participants in this group will receive two doses (IM) of RAZI recombinant spike protein vaccine 21 days apart followed by a nasal spray 51 days after the first dose (day 0).", "treatment_type": "TODO", "pharmacological_treatment": "TODO"}]

[{"arm_notes": "21 days apart followed by a nasal spray 51 days after the first dose (day 0)", "treatment_id": 1066, "treatment_name": "Razi cov pars", "treatment_type": "Protein subunit", "pharmacological_treatment": "Vaccine"}, {"arm_notes": "21 days apart followed by a nasal spray 51 days after the first dose (day 0)", "treatment_id": 1923, "treatment_name": "Inactivated sars-cov-2 vaccine (vero cell)", "treatment_type": "Inactivated virus", "pharmacological_treatment": "Vaccine"}]